Therapeutic study in 30 DLBCL cell lines with various molecular and genetic background found robust cytotoxicity of selinexor, especially in cells with BCL2-rearranged (BCL2-R<sup>+</sup>) DLBCL or high-grade B-cell lymphoma with MYC/BCL2 double-hit (HGBCL-DH). This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.